Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes

Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2011, Pages 819-829

  Lin, Yeong Liang ^a   Hsiao, Chia Ling ^a   Wu, Ya Chi ^a   Kung, Mei Fen ^a  

^a Center for Drug Evaluation   (Taiwan)

Author keywords

action potential duration; cutoff; human ether a go go related gene; QT; torsades de pointes

Indexed keywords

AMITRIPTYLINE; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; GATIFLOXACIN; GREPAFLOXACIN; HALOFANTRINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; MOXIFLOXACIN; OLANZAPINE; PAROXETINE; PENTAMIDINE; PIMOZIDE; POTASSIUM CHANNEL HERG; RISPERIDONE; RITONAVIR; SPARFLOXACIN; TELITHROMYCIN; TERFENADINE; THIORIDAZINE; ZIPRASIDONE;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; ELECTROPHYSIOLOGY; GRAPEFRUIT JUICE; HEART MUSCLE METABOLISM; HEART MUSCLE POTENTIAL; HUMAN; IC 50; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; POTASSIUM CURRENT; QT PROLONGATION; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; DRUG TOXICITY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; METABOLIC DETOXICATION, DRUG; MODELS, STATISTICAL; POTASSIUM CHANNELS, VOLTAGE-GATED; RISK FACTORS; ROC CURVE; TORSADES DE POINTES;

EID: 79955844082     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372521     Document Type: Article

References (50)

1. Redfern WS, Carlsson AS, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003 ; 58: 32-45 (Pubitemid 36351620)
2. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, Lynch JJ. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 ; 76: 110-119
3. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993 ; 269: 1513-1518 (Pubitemid 23086411)
4. Toyoshima S, Kanno A, Kitayama T, et al. QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci. 2005 ; 99: 459-471 (Pubitemid 44618147)
5. Delgado LF, Pferferman A, Sole D, Naspitz CK. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine and cetirizine in atopic children. Ann Allergy Asthma Immunol. 1998 ; 80: 333-337 (Pubitemid 28183592)
6. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998 ; 97: 204-210 (Pubitemid 28124679)
7. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?. J Pharmacol Exp Ther. 1997 ; 282: 220-227 (Pubitemid 27425544)
8. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B. Effects of cisapride on QT interval in children. J Pediatr. 1998 ; 133: 51-56 (Pubitemid 28323905)
9. van Haarst AD, van't Klooster GA, van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 1998 ; 64: 542-546 (Pubitemid 28531598)
10. Kang JS, Wang L, Chen X, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac k+ channel HERG. Mol Pharmacol. 2001 ; 59: 122-126 (Pubitemid 32043093)
11. Patmore L, Fraser S, Mair D, Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin and ciprofloxacin on cardiac action potential. Eur J Pharmacol. 2000 ; 406: 449-452
12. Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther. 1999 ; 288: 1261-1268 (Pubitemid 29254167)
13. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004 ; 24: 62-69 (Pubitemid 38134167)
14. Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther. 2001 ; 6: 255-260 (Pubitemid 34296588)
15. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999 ; 65: 10-20 (Pubitemid 29062024)
16. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Nordlie JW. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry. 1987 ; 144: 673-675 (Pubitemid 17067352)
17. Tie H, Walker BD, Singleton CB, et al. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol. 2000 ; 130: 1967-1975 (Pubitemid 30655810)
18. Mbai M, Rajamani S, January CT. The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels. Cardiovasc Res. 2002 ; 55: 799-805
19. Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 ; 72: 514-523 (Pubitemid 36237722)
20. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther. 2006 ; 318: 352-359
21. Stanat SJ, Carlton CG, Crumb WJ, Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem. 2003 ; 254: 1-7 (Pubitemid 37483735)
22. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 1995 ; 91: 3010-3016
23. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest. 1999 ; 115: 983-986 (Pubitemid 29193665)
24. Suessbrich H, Schönherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997 ; 120: 968-974 (Pubitemid 27122740)
25. Rasty S, Amin NB, Sabbah HN, Mishima T, Borzak S, Tisdale JE. Influence of i.v. haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs. Chest. 2004 ; 125: 1821-1829 (Pubitemid 38648417)
26. Drolet B, Zhang S, Deschenes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol. 1999 ; 10: 1597-1604 (Pubitemid 30020497)
27. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005 ; 102: 1094-1100 (Pubitemid 40745825)
28. Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol. 2001 ; 87: 231-234
29. Akita M, Shibazaki Y, Izumi M, et al. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci. 2004 ; 29: 63-71 (Pubitemid 38405099)
30. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Chest. 1998 ; 114: 120-130 (Pubitemid 28337372)
31. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005 ; 312: 316-323 (Pubitemid 40096484)
32. Cordes JS, Sun Z, Lloyd DB, et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol. 2005 ; 145: 15-23 (Pubitemid 40675544)
33. Girgis I, Gualberti J, Langan L, et al. A prospective study of the effect of iv pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest. 1997 ; 112: 646-652
34. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther. 2001 ; 296: 806-810 (Pubitemid 32187351)
35. Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community acquired pneumonia. Chest. 2005 ; 128: 3398-3406 (Pubitemid 41698670)
36. Gluais P, Bastide M, Caron J, Adamantidis M. Comparative effects of clarithromycin on action potential and ionic currents from rabbit isolated atrial and ventricular myocytes. J Cardiovasc Pharmacol. 2003 ; 41: 506-517 (Pubitemid 36373787)
37. Démolis JL, Vacheron F, Cardus S, Funck-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther. 2003 ; 73: 242-252 (Pubitemid 36269675)
38. Ducroq J, Printemps R, Le Grand M. Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbit Purkinje fibers and on the hERG potassium current. J Pharmacol Toxicol Methods. 2005 ; 52: 115-122 (Pubitemid 41008635)
39. Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Cardiovasc Pharmacol. 2003 ; 41: 934-937 (Pubitemid 36706143)
40. Jo SH, Youm JB, Lee CO, Earm YE, Ho WK. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol. 2000 ; 129: 1474-1480 (Pubitemid 30175721)
41. Claghorn JL, Schroeder J, Goldstein BJ. Comparison of the electrocardiographic effect of dothiepin and amitriptyline. J Clin Psychiatry. 1984 ; 45: 291-293 (Pubitemid 14090291)
42. Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol. 2007 ; 21: 735-741 (Pubitemid 47437909)
43. Hammond TG, Carlsson L, Davis AS, et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical company: results of an international survey. Cardiovasc Res. 2001 ; 49: 741-750 (Pubitemid 32178377)
44. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006 ; 316: 1098-1106 (Pubitemid 43345283)
45. Yang T, Snyders D, Roden DM. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001 ; 38: 737-744 (Pubitemid 32983280)
46. De Bruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005 ; 26: 590-597 (Pubitemid 40461101)
47. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol. 1996 ; 78 (suppl). 12-16
48. Kowey PR, Marinchak RA, Rials SJ, Bharucha DB. Classification and pharmacology of antiarrhythmic drugs. Am Heart J. 2000 ; 140: 12-20 (Pubitemid 30471236)
49. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004 ; 350: 1013-1022 (Pubitemid 38269278)
50. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol. 2002 ; 54: 188-202 (Pubitemid 35024944)